全文获取类型
收费全文 | 7354篇 |
免费 | 303篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 169篇 |
儿科学 | 139篇 |
妇产科学 | 197篇 |
基础医学 | 888篇 |
口腔科学 | 165篇 |
临床医学 | 498篇 |
内科学 | 1813篇 |
皮肤病学 | 169篇 |
神经病学 | 543篇 |
特种医学 | 147篇 |
外科学 | 1051篇 |
综合类 | 59篇 |
预防医学 | 645篇 |
眼科学 | 183篇 |
药学 | 388篇 |
中国医学 | 31篇 |
肿瘤学 | 607篇 |
出版年
2023年 | 45篇 |
2022年 | 94篇 |
2021年 | 223篇 |
2020年 | 118篇 |
2019年 | 211篇 |
2018年 | 221篇 |
2017年 | 134篇 |
2016年 | 147篇 |
2015年 | 170篇 |
2014年 | 259篇 |
2013年 | 347篇 |
2012年 | 572篇 |
2011年 | 610篇 |
2010年 | 350篇 |
2009年 | 358篇 |
2008年 | 533篇 |
2007年 | 531篇 |
2006年 | 454篇 |
2005年 | 481篇 |
2004年 | 433篇 |
2003年 | 355篇 |
2002年 | 398篇 |
2001年 | 44篇 |
2000年 | 37篇 |
1999年 | 57篇 |
1998年 | 49篇 |
1997年 | 49篇 |
1996年 | 42篇 |
1995年 | 29篇 |
1994年 | 36篇 |
1993年 | 37篇 |
1992年 | 20篇 |
1991年 | 19篇 |
1990年 | 13篇 |
1989年 | 18篇 |
1988年 | 19篇 |
1987年 | 7篇 |
1986年 | 14篇 |
1985年 | 9篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 19篇 |
1980年 | 13篇 |
1979年 | 5篇 |
1978年 | 10篇 |
1976年 | 6篇 |
1975年 | 5篇 |
1974年 | 9篇 |
1973年 | 5篇 |
1971年 | 6篇 |
排序方式: 共有7692条查询结果,搜索用时 15 毫秒
71.
72.
Enrique Teran Carlos Escudero Sandra Vivero Armando Enriquez Andres Calle 《Hypertension in pregnancy》2004,23(3):303-308
OBJECTIVE: To investigate the intraplatelet cyclic guanosine-3',5'-monophosphate (cGMP) levels during normal pregnancy and preeclampsia. STUDY DESIGN: Pregnant women (n = 15), women with preeclampsia (n = 15), and nonpregnant, normotensive women (n = 15) were included. Intraplatelet cyclic guanosine-3',5'-monophosphate levels were measured by an enzyme-linked immunosorbent assay. RESULTS: Intraplatelet cGMP levels were significantly different among all groups (p < 0.02). The values were higher in normal pregnant women (mean 19.8 SD 2.6 fmol/10(5) platelets) in comparison to nonpregnant women (mean 7.6 SD 0.3 fmol/10(5)platelets; p = 0.001) and women with preeclampsia (mean 11.3 SD 1.8 fmol/10(5) platelets; p = 0.05). Plasma nitric oxide levels did not reveal differences between all groups. CONCLUSIONS: The results of this study in a high-risk Andean population demonstrated that intraplatelet cyclic guanosine-3',5'-monophosphate levels are decreased during preeclampsia compared to normal pregnancy, suggesting a lack in action of nitric oxide. 相似文献
73.
Fernando Arias de la Vega Miguel Angel Domínguez Domínguez Ana Manterola Burgaleta Ruth Vera García Maria Eugenia Echeverría Zabalza Eugenio Oria Mundin Enrique Martínez López Pilar Romero Rojano Elena Villafranca Iture 《Clinical & translational oncology》2005,7(2):60-65
INTRODUCTION: This study aims to asses the effectiveness and toxicity of boost radiotherapy concomitant and concurrent cisplatin for patients with locally advanced head and neck cancer (LAHNC). MATERIAL AND METHODS: There were 30 patients included in a prospective, phase II single-institution trial and of whom, 29 were at AJCC stage IV and 1 at stage III. Treatment consisted of radiotherapy acceleration fractionation with concomitant boost, 72 Gy, and 2 cycles of concomitant cisplatin (20 mg/m2/day continuous infusion; days 1-5 and 29-33). Amifostine, (i.v. 200 mg/m2) was administered to 26 prior to the first fraction of radiotherapy. Endpoints of the study were quality-of-life (QL), overall survival, and local control of disease. RESULTS: Complete response (CR) was achieved in 23 patients (77%), 2 patients had partial response (PR) (7%), 4 had no response (13%), and 1 was not evaluated for response. The 2-year overall survival and loco-regional control were 60% and 56%, respectively. Main toxicity was grade 3 or 4 mucositis in 93% of the patients. QL scores (questionnaire QLQC30; version 3.0) and the HN cancer module QLQ-HN35) showed a worsening in areas related to the treatment e.g. dry mouth, problems stretching the mouth, and sticky saliva. CONCLUSIONS: this combination modality is active, but toxic, in the treatment for LAHNC. Concomitant boost radiotherapy is probably, not the best radiotherapy schema for combining with chemotherapy in LAHNC. 相似文献
74.
Javier Sastre Eugenio Marcuello Bartomeu Masutti Matilde Navarro Silvia Gil Antonio Antón Albert Abad Enrique Aranda Joan Maurel Manuel Valladares Inmaculada Maestu Alfredo Carrato José María Vicent Eduardo Díaz-Rubio 《Journal of clinical oncology》2005,23(15):3545-3551
PURPOSE: Elderly patients constitute a subpopulation with special characteristics that differ from those of the nonelderly and have been underrepresented in clinical trials. This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients. PATIENTS AND METHODS: Patients > or = 72 years old with metastatic colorectal cancer, Eastern Cooperative Oncology Group performance status of 0 to 1, no geriatric syndromes, and no prior treatment were treated every 2 weeks with CPT-11 180 mg/m2 plus FU 3,000 mg/m2 in a 48-hour continuous infusion. RESULTS: By intent-to-treat analysis, in 85 assessable patients, the objective response rate was 35% (95% CI, 25% to 46%), and stable disease was 33% (95% CI, 23% to 44%). Median time to progression was 8.0 months (95% CI, 6.0 to 10.0 months), and median overall survival time was 15.3 months (95% CI, 13.8 to 16.9 months). Toxicity was moderate. Grade 3 and 4 neutropenia, diarrhea, and asthenia were observed in 21%, 17%, and 13% of patients, respectively. Only one case of neutropenic fever occurred. There were two toxic deaths, one was a result of grade 4 diarrhea and acute kidney failure, and the other was a result of massive intestinal hemorrhage in the first cycle. The study of prognostic factors did not reveal any predictive factor of response. Response to treatment and baseline lactate dehydrogenase were the main factors conditioning progression-free and overall survival. CONCLUSION: Twice a month continuous-infusion CPT-11 combined with FU is a valid therapeutic alternative for elderly patients in good general condition. 相似文献
75.
76.
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. 总被引:2,自引:0,他引:2
Emiliano Honrado Ana Osorio José Palacios Roger L Milne Lydia Sánchez Orland Díez Alicia Cazorla Kirsi Syrjakoski David Huntsman P?ivi Heikkil? Enrique Lerma Anne Kallioniemi Carmen Rivas William D Foulkes Heli Nevanlinna Javier Benítez 《Journal of clinical oncology》2005,23(30):7503-7511
PURPOSE: Morphologic and immunohistochemical studies of familial breast cancers have identified specific characteristics associated with BRCA1 mutation-associated tumors when compared with BRCA2 and non-BRCA1/2 tumors, but have not identified differences between BRCA2 and non-BRCA1/2 tumors. Because BRCA1 and BRCA2 genes participate in the DNA repair pathway, we have performed an immunohistochemical study with markers related to this pathway to establish the profile of the three groups. MATERIALS AND METHODS: We have studied two tissue microarrays that include 103 familial and 104 sporadic breast tumors, with a panel of DNA repair markers including ATM, CHEK2, RAD51, RAD50, XRCC3, and proliferating cell nuclear antigen. RESULTS: We found more frequent expression of CHEK2 in BRCA1 and BRCA2 tumors than in non-BRCA1/2 and sporadic tumors. We found absence of nuclear expression and presence of cytoplasmic expression of RAD51 in BRCA2 tumors that differentiate them from other familial tumors. We validated these results with a new series of patient cases. The final study with 253 familial patient cases (74 BRCA1, 71 BRCA2, 108 non-BRCA1/2), and 288 sporadic patient cases, has allowed us to confirm our preliminary results. Because BRCA2 tumors present a specific immunohistochemical profile for RAD51 and CHEK2 markers that is different from non-BRCA1/2 tumors, we have built a multivariate model with these markers that distinguish both tumors with an estimated probability of at least 76%. CONCLUSION: Our results suggest that BRCA2 tumors demonstrate more cytoplasmic and less nuclear RAD51 staining, and increased CHEK2 staining. This pattern may distinguish BRCA2 from familial non-BRCA1/2 tumors. 相似文献
77.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays 下载免费PDF全文
David M. Hyams MD Eric Schuur PhD Javier Angel Aristizabal MD Juan Enrique Bargallo Rocha MD Cesar Cabello MD Roberto Elizalde MD Laura García‐Estévez MD Henry L. Gomez MD Artur Katz MD Aníbal Nuñez De Pierro MD 《Journal of surgical oncology》2017,115(6):647-662
Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision‐making. This review details the development and validation of six multi‐gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use. 相似文献
78.
R Salazar M Navarro F Losa V Alonso M Gallén F Rivera M Benavides P Escudero E González B Massutí A Gómez M Majem E Aranda 《Clinical & translational oncology》2012,14(8):592-598
Introduction
A prospective phase II study was conducted to assess the clinical activity and tolerability of oxaliplatin, capecitabine, and radiotherapy (RT) for neoadjuvant therapy of stages II?CIII rectal cancer.Materials and methods
Patients with histologically confirmed stages II?CIII (T3?CT4 and/or N+) resectable rectal adenocarcinoma were eligible. Capecitabine was administered at 825?mg/m2 twice daily for 5?days/week and oxaliplatin at 50?mg/m2 on day 1 weekly for 5?weeks starting the first day of RT (before RT). RT consisted of a total dose of 45?Gy delivered in 25 fractions of 1.8?Gy, 5?days per week, for 5?weeks.Results
A total of 46 patients were included (35 male, 10 female, median age 62?years). TNM Stage was T3 in 43 patients and T4 in 2. Twenty-eight patients had suspected nodal involvement. The intended chemoradiation treatment was completed in 94?% patients. Grade 3/4 toxicity included lymphocytopenia (6 patients), diarrhea (4 patients), emesis (2 patients), asthenia (3 patients), anorexia (1 patient), and hepatic toxicity (1 patient). Grade 1 neurotoxicity occurred in 18 patients, Grade 2 neurotoxicity in 3, and Grade 1 palmoplantar erythrodysesthesia in 2. Forty-two patients underwent surgery (complete resection 95?%, sphincter-saving operation 55?%). The overall pathologic response rate was 83?%, with a pathologic complete response (pCR) rate of 11.9?% (95?% CI 4.0?C25.6).Conclusions
The pCR rate observed with oxaliplatin plus capecitabine and RT did not reach the pre-specified criteria of efficacy in this trial, which is in line with recent results of randomized phase III trials. 相似文献79.
James Larkin Michele Del Vecchio Paolo A Ascierto Ivana Krajsova Jacob Schachter Bart Neyns Enrique Espinosa Claus Garbe Vanna Chiarion Sileni Helen Gogas Wilson H Miller Mario Mandalà Geke A P Hospers Ana Arance Paola Queirolo Axel Hauschild Michael P Brown Lada Mitchell Christian U Blank 《The lancet oncology》2014,15(4):436-444
80.
Prada Diddier Baccarelli Andrea A. Terry Mary Beth Valdéz Leonora Cabrera Paula Just Allan Kloog Itai Caro Haydee García-Cuellar Claudia Sánchez-Pérez Yesennia Cruz Rodrigo Diaz-Chávez Jose Cortés Carlo Pérez Delia Meneses-García Abelardo Cantú-de-León David Herrera Luis A. Bargalló Enrique 《Breast cancer research and treatment》2021,187(2):525-533
Breast Cancer Research and Treatment - Many patients seek breast reconstruction following mastectomy. Debate exists regarding the best reconstructive option. The authors evaluate outcomes comparing... 相似文献